5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Piramal Pharma Ltd.

•
piramalpharma.comBSE: 543635NSE: PPLPHARMA
Market Cap₹ 28,125 Cr.
Current Price
High / Low₹ 232 / 132
Stock P/E—
Book Value₹ 60
Price to Book2.24
Dividend Yield0.00 %
ROCE1.2 %
ROE-4.0 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company generates healthy free cash flow

CONS

  • Company is loss-making at the operating / net level
  • Recent results are weak - TTM profit is down 373.7% versus prior year
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -16.36x)
  • Company has a low return on equity of -0.9% over last 3 years
  • Company has a low return on capital employed of 4.3%
  • Interest coverage is weak at 0.5x - earnings barely cover interest

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY PHARMANIFTY TOTAL MKTNIFTY SMLCAP 50NIFTY 500NIFTY SMLCAP 250
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.PPLPHARMA211.2540.1628124.730.00-69.3915.072269.9217.391.249.46
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
1,7491,9111,9592,5521,9512,2422,2042,7541,9342,0442,1402,7522,270
1,6171,6461,6902,0221,7471,9001,8662,1931,8271,8851,9442,2912,386
Operating Profit132266268530204342338561107159196461-116
OPM %7.57%13.90%13.70%20.76%10.48%15.24%15.32%20.37%5.52%7.76%9.15%16.74%-5.13%
384929-42061124279662-13089
Interest1191101061141071081031048682898388
Depreciation174185186196185192197243197203213218224
Profit before Tax-122205215-6710350257-98-61-10429-7
Tax %7.02%168.90%170.98%58.58%-64.55%94.82%126.87%46.50%-2.75%-86.99%-40.66%176.11%-830.16%
Net Profit0000-8922637154-82-99-136-88-69
-0.810.040.080.77-0.670.170.031.16-0.62-0.75-1.03-0.07-0.52

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
6,3156,5597,0828,1719,1518,8699,205
4,8875,6096,4537,0017,7337,9778,507
Operating Profit1,4289506281,1711,418892698
OPM %22.61%14.48%8.87%14.32%15.49%10.06%7.59%
1822612181381624627
Interest163198344448422341343
Depreciation545586677741816831858
Profit before Tax949485-120179415-176-143
Tax %12.01%22.48%-55.19%90.06%78.02%-85.13%-146.12%
Net Profit835376-1861891-326-352
EPS13.303.19-1.540.130.69-2.46—
Dividend Payout %0.00%0.00%0.00%81.66%20.35%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
7%
3 Years:
8%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
—
3 Years:
—

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
28%
1 Year:
6%

RETURN ON EQUITY

10 Years:
—
5 Years:
0%
3 Years:
-1%
Last Year:
-4%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2025

Jul 16

₹ 0.01

Rs.0.1400 per share(1.4%)Final Dividend

2024

Jul 12

₹ 0.01

Rs.0.1100 per share(1.1%)Final Dividend

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital9951,1861,1931,3231,3241,327
4,6105,5115,5806,5616,7396,763
2,9363,5214,9683,9414,4845,339
Trade Payables9181,0261,1931,5381,5342,479
1,2971,4731,5021,5621,2881,658
Total Liabilities10,75612,71714,43714,92515,36917,567
6,1056,8797,4697,9908,1338,684
Capital Work in Progress400673853566489799
123267639385291437
1,2321,3891,6812,1762,3133,064
0002,1342,3502,158
Cash & Bank4063293084835011,224
2,4913,1803,4871,1921,2921,201
Total Assets10,75612,71714,43714,92515,36917,567

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
7429366731,0058921,653
Cash from Investing-4,480-1,812-1,339-434-477-826
Cash from Financing3,977794818-422-441-39
94-251-37148-26788

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
34.9534.9534.9534.9534.8634.8634.8634.8634.80
31.4131.7331.6831.4930.8630.2729.6630.1712.51
12.9513.8014.0914.7814.2514.8915.6915.6114.57
Government0.000.000.000.000.000.000.000.000.00
20.6919.5219.2718.7820.0319.9819.7919.3638.11

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-08 - Intimation of Schedule of Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

2026-09-03
General Updates

2026-09-03 - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating

2026-08-24
Updates

2026-08-24 - Sustainability Report of Piramal Pharma Limited ( the Company ) for thefinancial year 2025-26-26

2026-08-18
Acquisition

2026-08-18 - Piramal Pharma Limited has informed the Exchange about Acquisition

2026-08-10
Updates

2026-08-10 - Piramal Pharma Limited has informed the Exchange regarding 'Exercise of call option for acquisition of additional equity stake in Yapan Bio PrivateLimited'.

2026-08-10
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-10 - Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

2026-08-03
Updates

2026-08-03 - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Resumption of operations at Company s facilities located at Ahmedabad, Gujarat

2026-07-31
Analysts/Institutional Investor Meet/Con. Call Updates

2026-07-31 - Piramal Pharma Limited has informed the Exchange about Transcript

2026-07-30
Shareholders meeting

2026-07-30 - Proceedings and Voting Results of the 6th Annual General Meeting of the Company

News

Recent coverage and analyst commentary for PPLPHARMA

Loading news…

🤖

AI Stock Analyst

Piramal Pharma Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme


5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login